Candel Therapeutics Statistics
Total Valuation
CADL has a market cap or net worth of $770.07 million. The enterprise value is $624.51 million.
| Market Cap | 770.07M |
| Enterprise Value | 624.51M |
Important Dates
The next estimated earnings date is Friday, August 14, 2026, before market open.
| Earnings Date | Aug 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CADL has 73.27 million shares outstanding. The number of shares has increased by 51.17% in one year.
| Current Share Class | 73.27M |
| Shares Outstanding | 73.27M |
| Shares Change (YoY) | +51.17% |
| Shares Change (QoQ) | +13.60% |
| Owned by Insiders (%) | 8.12% |
| Owned by Institutions (%) | 55.64% |
| Float | 56.81M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 5.58 |
| P/TBV Ratio | 5.58 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 28.05, with a Debt / Equity ratio of 0.36.
| Current Ratio | 28.05 |
| Quick Ratio | 27.63 |
| Debt / Equity | 0.36 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -16.71 |
Financial Efficiency
Return on equity (ROE) is -51.17% and return on invested capital (ROIC) is -25.80%.
| Return on Equity (ROE) | -51.17% |
| Return on Assets (ROA) | -23.64% |
| Return on Invested Capital (ROIC) | -25.80% |
| Return on Capital Employed (ROCE) | -28.95% |
| Weighted Average Cost of Capital (WACC) | 1.72% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$989,491 |
| Employee Count | 55 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +67.09% in the last 52 weeks. The beta is -0.50, so CADL's price volatility has been lower than the market average.
| Beta (5Y) | -0.50 |
| 52-Week Price Change | +67.09% |
| 50-Day Moving Average | 9.26 |
| 200-Day Moving Average | 6.58 |
| Relative Strength Index (RSI) | 60.65 |
| Average Volume (20 Days) | 1,252,339 |
Short Selling Information
The latest short interest is 12.96 million, so 17.69% of the outstanding shares have been sold short.
| Short Interest | 12.96M |
| Short Previous Month | 16.14M |
| Short % of Shares Out | 17.69% |
| Short % of Float | 22.82% |
| Short Ratio (days to cover) | 6.28 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -56.33M |
| Pretax Income | -54.42M |
| Net Income | -54.42M |
| EBITDA | -55.67M |
| EBIT | -56.42M |
| Earnings Per Share (EPS) | -$0.97 |
Balance Sheet
The company has $194.83 million in cash and $49.27 million in debt, with a net cash position of $145.56 million or $1.99 per share.
| Cash & Cash Equivalents | 194.83M |
| Total Debt | 49.27M |
| Net Cash | 145.56M |
| Net Cash Per Share | $1.99 |
| Equity (Book Value) | 138.03M |
| Book Value Per Share | 1.88 |
| Working Capital | 190.70M |
Cash Flow
In the last 12 months, operating cash flow was -$47.73 million and capital expenditures -$1.26 million, giving a free cash flow of -$48.99 million.
| Operating Cash Flow | -47.73M |
| Capital Expenditures | -1.26M |
| Depreciation & Amortization | 749,000 |
| Net Borrowing | 38.71M |
| Free Cash Flow | -48.99M |
| FCF Per Share | -$0.67 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CADL does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -51.17% |
| Shareholder Yield | -51.17% |
| Earnings Yield | -7.07% |
| FCF Yield | -6.36% |
Analyst Forecast
The average price target for CADL is $20.50, which is 95.05% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $20.50 |
| Price Target Difference | 95.05% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |